Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-trapping” Antibody for the Treatment of COVID-19
DURHAM, N.C., May 26, 2021 /PRNewswire/ — Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating a variety of acute respiratory infections (ARI), today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients. IN-006 is a potent, neutralizing monoclonal antibody being investigated for the treatment of COVID-19. Initial results of this study are expected in 2022.